Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs

Pharmacology and Therapeutics

Volumn 140, Issue 1, 2013, Pages 10-25

  Gavioli, Elaine Cristina ^a   Calo', Girolamo ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

5 HT neurotransmission; FQ; Mood disorders; Nociceptin orphanin; NOP antagonists; NOP receptor; Stress

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; ANTIDEPRESSANT AGENT; CORTICOSTERONE; IMIPRAMINE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; NORADRENALIN; PAROXETINE; UFP 101; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; BIPOLAR DEPRESSION; BIPOLAR MANIA; CIRCADIAN RHYTHM; CORTICOSTERONE BLOOD LEVEL; CRYSTAL STRUCTURE; DENTATE GYRUS; DEPRESSION; DIAGONAL BAND OF BROCA; DOPAMINE RELEASE; DORSAL RAPHE NUCLEUS; FOOD INTAKE; FREE WATER CLEARANCE; HABENULA; HEART FAILURE; HIPPOCAMPUS; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; LOCUS CERULEUS; LONG TERM EXPOSURE; MEDIAL PREOPTIC AREA; MOOD DISORDER; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NOCICEPTIVE STIMULATION; NONHUMAN; NORADRENALIN BLOOD LEVEL; ORBITAL CORTEX; PAIN THRESHOLD; PHENOTYPE; PHENOTYPIC VARIATION; PLACE PREFERENCE; PLASTICITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUERPERAL DEPRESSION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STRESS; SODIUM URINE LEVEL; STRIA TERMINALIS; SUPRACHIASMATIC NUCLEUS; VENTRAL TEGMENTUM;

5-HT; 5-HT NEUROTRANSMISSION; ACCUMBENS NUCLEUS; ACTH; ADRENOCORTICOTROPIC HORMONE; AMY; AMYGDALA; BDNF; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASE FACTOR; CRF; DORSAL RAPHE NUCLEUS; DRN; HIPP; HIPPOCAMPUS; HPA; HYPOTHALAMUS-PITUITARY-ADRENAL AXIS; LC; LOCUS CERULEUS; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; MOOD DISORDERS; N/OFQ; NAC; NOCICEPTIN/ORPHANIN FQ; NOCICEPTIN/ORPHANIN FQ PEPTIDE RECEPTOR; NOP ANTAGONISTS; NOP RECEPTOR; NTS; NUCLEUS OF THE SOLITARY TRACT; PFC; POMC; PPN/OFQ; PREFRONTAL CORTEX; PREPRONOCICEPTIN/ORPHANIN FQ; PROOPIOMELANOCORTIN; SEROTONIN; STRESS; VENTRAL TEGMENTAL AREA; VTA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; HUMANS; MOOD DISORDERS; OPIOID PEPTIDES; RECEPTORS, OPIOID; STRESS, PSYCHOLOGICAL;

EID: 84883796419     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.05.008     Document Type: Review

References (235)

1. D. Aarsland, L. Marsh, and A. Schrag Neuropsychiatric symptoms in Parkinson's disease Mov Disord 24 15 2009 2175 2186
2. D. Aarsland, S. Påhlhagen, C.G. Ballard, U. Ehrt, and P. Svenningsson Depression in Parkinson disease - epidemiology, mechanisms and management Nat Rev Neurol 8 1 2011 35 47
3. M. Adachi, M. Barrot, A.E. Autry, D. Theobald, and L.M. Monteggia Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy Biol Psychiatry 63 2008 642 649
4. G. Aguilera, Q. Pham, and C. Rabadan-Diehl Regulation of pituitary vasopressin receptors during chronic stress: relationship to corticotroph responsiveness J Neuroendocrinol 6 3 1994 299 304
5. J. Alfonso, A.C. Frasch, and G. Flugge Chronic stress, depression and antidepressants: effects on gene transcription in the hippocampus Rev Neurosci 16 1 2005 43 56
6. C.N. Allen, Z.G. Jiang, K. Teshima, T. Darland, M. Ikeda, and C.S. Nelson Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons J Neurosci 19 6 1999 2152 2160
7. C. Alt, J.S. Lam, M.T. Harrison, K.M. Kershaw, S. Samuelsson, and L. Toll Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis Eur J Pharmacol 683 1-3 2012 285 293
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Press Washington (DC)
9. B. Anton, J. Fein, T. To, X. Li, L. Silberstein, and C.J. Evans Immunohistochemical localization of ORL-1 in the central nervous system of the rat J Comp Neurol 368 2 1996 229 251
10. M. Antonioli, J. Rybka, and L.A. Carvalho Neuroimmune endocrine effects of antidepressants J Neuropsychiatr Dis Treat 8 2012 65 83
11. M. Basso, P.A. Risse, E. Naline, G. Calo, R. Guerrini, and D. Regoli Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation Peptides 26 2005 1492 1496
12. S. Bekris, K. Antoniou, S. Daskas, and Z. Papadopoulou-Daifoti Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains Behav Brain Res 161 1 2005 45 59
13. A. Berthele, S. Platzer, D. Dworzak, J. Schadrack, B. Mahal, and A. Buttner [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain Neuroscience 121 2003 629 640
14. O. Berton, and E.J. Nestler New approaches to antidepressant drug discovery: beyond monoamines Nat Rev Neurosci 7 2 2006 137 151
15. I.P. Berzetei-Gurske, R.W. Schwartz, and L. Toll Determination of activity for nociceptin in the mouse vas deferens Eur J Pharmacol 302 1996 R1 R2
16. R. Bigoni, G. Calo, A. Rizzi, R. Guerrini, C. De Risi, and Y. Hashimoto In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist Naunyn Schmiedebergs Arch Pharmacol 361 2000 565 568
17. R. Bigoni, S. Giuliani, G. Calo', A. Rizzi, R. Guerrini, and S. Salvadori Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies Naunyn Schmiedebergs Arch Pharmacol 359 1999 160 167
18. D.C. Bolser, R.L. McLeod, D.B. Tulshian, and J.A. Hey Antitussive action of nociceptin in the cat Eur J Pharmacol 430 2001 107 111
19. A. Boom, C. Mollereau, J.C. Meunier, G. Vassart, M. Parmentier, and J.J. Vanderhaeghen Distribution of the nociceptin and nocistatin precursor transcript in the mouse central nervous system Neuroscience 91 3 1999 991 1007
20. M. Bourin, A.J. Fiocco, and F. Clenet How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16 2001 9 21
21. M.R. Bruchas, A.G. Schindler, H. Shankar, D.I. Messinger, M. Miyatake, and B.B. Land Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction Neuron 71 3 2011 498 511
22. M.A. Burmeister, M.A. Ansonoff, J.E. Pintar, and D.R. Kapusta Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension and diuresis are absent in N/OFQ peptide (NOP) receptor knockout (NOP-/-) mice J Pharmacol Exp Ther 326 3 2008 897 904
23. M.A. Burmeister, and D.R. Kapusta Centrally administered nociceptin/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors J Pharmacol Exp Ther 322 1 2007 324 331
24. B. Buwalda, M.H. Kole, A.H. Veenema, M. Huininga, S.F. de Boer, and S.M. Korte Long-term effects of social stress on brain and behavior: a focus on hippocampal functioning Neurosci Biobehav Rev 29 1 2005 83 97
25. G. Calo, R. Guerrini, A. Rizzi, S. Salvadori, M. Burmeister, and D.R. Kapusta UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor CNS Drug Rev 11 2005 97 112
26. G. Calo', R. Guerrini, R. Bigoni, A. Rizzi, G. Marzola, and H. Okawa Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist Br J Pharmacol 129 2000 1183 1193
27. G. Calo', R. Guerrini, A. Rizzi, S. Salvadori, and D. Regoli Pharmacology of nociceptin and its receptor: a novel therapeutic target Br J Pharmacol 129 2000 1261 1283
28. G. Calo', A. Rizzi, G. Bogoni, V. Neugebauer, S. Salvadori, and R. Guerrini The mouse vas deferens: a pharmacological preparation sensitive to nociceptin Eur J Pharmacol 311 1 1996 R3 R5
29. G. Calo', A. Rizzi, D. Rizzi, R. Bigoni, R. Guerrini, and G. Marzola [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor Br J Pharmacol 136 2002 303 311
30. V. Camarda, C. Fischetti, N. Anzellotti, P. Molinari, C. Ambrosio, and E. Kostenis Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5 Naunyn Schmiedebergs Arch Pharmacol 379 2009 599 607
31. G. Carrà, A. Rizzi, R. Guerrini, T.A. Barnes, J. McDonald, and C.P. Hebbes [(pF)Phe4, Arg14, Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor J Pharmacol Exp Ther 312 3 2005 1114 1123
32. A. Ces, D. Reiss, O. Walter, J. Wichmann, E.P. Prinssen, and B.L. Kieffer Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists Neuropsychopharmacology 37 2012 378 389
33. Y. Chen, M. Chang, Z.Z. Wang, L.X. Chen, Q. Yang, and Y.M. Qi [Nphe1]nociceptin(1-13)-NH2 antagonizes nociceptin-induced hypotension, bradycardia, and hindquarters vasodilation in the anesthetized rat Can J Physiol Pharmacol 80 2002 31 35
34. R. Ciccocioppo, A. Fedeli, D. Economidou, F. Policani, F. Weiss, and M. Massi The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ J Neurosci 23 28 2003 9445 9451
35. R. Ciccocioppo, R. Martin-Fardon, F. Weiss, and M. Massi Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats Neuroreport 12 6 2001 1145 1149
36. M. Connor, C.W. Vaughan, B. Chieng, and M.J. Christie Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro Br J Pharmacol 119 1996 1614 1618
37. M. Connor, C.W. Vaughan, E.A. Jennings, R.G. Allen, and M.J. Christie Nociceptin, Phe(1)psi-nociceptin(1-13), nocistatin and prepronociceptin(154-181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro Br J Pharmacol 128 8 1999 1779 1787
38. M. Connor, A. Yeo, and G. Henderson The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line Br J Pharmacol 118 2 1996 205 207
39. B.M. Cox, C. Chavkin, M.J. Christie, O. Civelli, C. Evans, and M.D. Hamon Opioid receptors D. Girdlestone, The IUPHAR compendium of receptor characterization and classification 2nd ed. 2000 IUPHAR Media London 321 333
40. M.T. Cruz, M.A. Herman, M. Kallupi, and M. Roberto Nociceptin/Orphanin FQ blockade of corticotropin-releasing factor-induced gamma-aminobutyric acid release in central amygdala is enhanced after chronic ethanol exposure Biol Psychiatry 71 8 2012 666 676
41. M. Cuesta, D. Clesse, P. Pévet, and E. Challet New light on the serotonergic paradox in the rat circadian system J Neurochem 110 1 2009 231 243
42. B. D'Agostino, G. Marrocco, M. De Nardo, G. Calo, R. Guerrini, and L. Gallelli Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux Br J Pharmacol 144 6 2005 813 820
43. K.L. Dawe, J.B. Wakerley, and A.J. Fulford Nociceptin/orphanin FQ and the regulation of neuronal excitability in the rat bed nucleus of the stria terminalis: interaction with glucocorticoids Stress 13 6 2010 516 527
44. C. de Bodinat, B. Guardiola-Lemaitre, E. Mocaër, P. Renard, C. Muñoz, and M.J. Millan Agomelatine, the first melatonergic antidepressant: discovery, characterization and development Nat Rev Drug Discov 9 8 2010 628 642
45. C. de Montigny, Y. Chaput, and P. Blier Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers J Clin Psychiatry 51 Suppl. B 1990 4 8
46. U.B. Depner, R.K. Reinscheid, H. Takeshima, K. Brune, and H.U. Zeilhofer Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor Eur J Neurosci 17 11 2003 2381 2387
47. D.P. Devine, M.T. Hoversten, Y. Ueda, and H. Akil Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress J Neuroendocrinol 15 1 2003 69 74
48. D.P. Devine, S.J. Watson, and H. Akil Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic-pituitary-adrenal axis Neuroscience 102 3 2001 541 553
49. C. D'Sa, and R.S. Duman Antidepressants and neuroplasticity Bipolar Disord 4 3 2002 183 194
50. R.S. Duman Role of neurotrophic factors in the etiology and treatment of mood disorders Neuromolecular Med 5 1 2004 11 25
51. G.J. Dumont, S.J. de Visser, A.F. Cohen, J.M. van Gerven Biomarker Working Group of the German Association for Applied Human Pharmacology Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects Br J Clin Pharmacol 59 5 2005 495 510
52. M. Duzzioni, F.S. Duarte, L.R. Leme, E.C. Gavioli, and T.C. De Lima Anxiolytic-like effect of central administration of NOP receptor antagonist UFP-101 in rats submitted to the elevated T-maze Behav Brain Res 222 1 2011 206 211
53. K. Dzirasa, and H.E. Covington III Increasing the validity of experimental models for depression Ann N Y Acad Sci 1265 2012 36 45
54. M. El Mansari, C. Sánchez, G. Chouvet, B. Renaud, and N. Haddjeri Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain Neuropsychopharmacology 30 7 2005 1269 1277
55. J. Emens, A. Lewy, J.M. Kinzie, D. Arntz, and J. Rough Circadian misalignment in major depressive disorder Psychiatry Res 168 3 2009 259 261
56. C. Faisy, E. Naline, C. Rouget, P.A. Risse, E. Guerot, and J.Y. Fagon Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi Naunyn Schmiedebergs Arch Pharmacol 370 3 2004 167 175
57. M. Fantin, C. Fischetti, C. Trapella, and M. Morari Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways Br J Pharmacol 152 4 2007 549 555
58. F. Fernandez, M.A. Misilmeri, J.C. Felger, and D.P. Devine Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety Neuropsychopharmacology 29 1 2004 59 71
59. M. Filaferro, S. Zucchini, V. Ruggieri, G. Vitale, C. Novi, and C. Cifani Effects of the continuous delivery of a potent NOP receptor antagonist, [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), on molecular, cellular and behavioral alterations in a chronic model of stress 35 Congresso Nazionale della società Italiana di Farmacologia; Bologna 14-17 settembre, P-5/39 2011
60. M. Filizola, and L.A. Devi Structural biology: how opioid drugs bind to receptors Nature 485 2012 314 317
61. C. Fischetti, V. Camarda, A. Rizzi, M. Pelà, C. Trapella, and R. Guerrini Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 Eur J Pharmacol 614 1-3 2009 50 57
62. S. Florin, J. Meunier, and J. Costentin Autoradiographic localization of [3H]nociceptin binding sites in the rat brain Brain Res 880 1-2 2000 11 16
63. T. Fujino, Z. Wu, W.C. Lin, M.A. Phillips, and E. Nedivi cpg15 and cpg15-2 constitute a family of activity-regulated ligands expressed differentially in the nervous system to promote neurite growth and neuronal survival J Comp Neurol 507 2008 1831 1845
64. E.C. Gavioli, and G. Calo' Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands Naunyn Schmiedebergs Arch Pharmacol 372 5 2006 319 330
65. E.C. Gavioli, F.S. Duarte, R. Guerrini, G. Calo, G.A. Rae, and T.C. De Lima GABA(A) signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze Peptides 29 8 2008 1404 1412
66. E.C. Gavioli, G. Marzola, R. Guerrini, R. Bertorelli, S. Zucchini, and T.C. De Lima Blockade of nociceptin/orphanin FQ-NOP receptor signaling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test Eur J Neurosci 17 2003 1987 1990
67. E.C. Gavioli, G.A. Rae, G. Calo', R. Guerrini, and T.C. De Lima Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test Br J Pharmacol 136 5 2002 764 772
68. E.C. Gavioli, A. Rizzi, G. Marzola, S. Zucchini, D. Regoli, and G. Calo' Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice Peptides 28 6 2007 1229 1239
69. E.C. Gavioli, and P.R. Romão NOP receptor ligands as potential agents for inflammatory and autoimmune diseases J Amino Acids 2011 2011 836569
70. E.C. Gavioli, C.W. Vaughan, G. Marzola, R. Guerrini, V.A. Mitchell, and S. Zucchini Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice Naunyn Schmiedebergs Arch Pharmacol 369 2004 547 553
71. S. Giuliani, A. Lecci, M. Tramontana, and C.A. Maggi The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats Br J Pharmacol 124 1998 1566 1572
72. S. Giuliani, A. Lecci, M. Tramontana, and C.A. Maggi Nociceptin protects capsaicin-sensitive afferent fibers in the rat urinary bladder from desensitization Naunyn Schmiedebergs Arch Pharmacol 360 2 1999 202 208
73. C. Goeldner, D. Reiss, B.L. Kieffer, and A.M. Ouagazzal Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior Hippocampus 20 8 2010 911 916
74. C. Goeldner, W. Spooren, J. Wichmann, and E.P. Prinssen Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair Psychopharmacology (Berl) 222 2 2012 203 214
75. H.S. Gompf, M.G. Moldavan, R.P. Irwin, and C.N. Allen Nociceptin/orphanin FQ (N/OFQ) inhibits excitatory and inhibitory synaptic signaling in the suprachiasmatic nucleus (SCN) Neuroscience 132 4 2005 955 965
76. P. Gorwood Restoring circadian rhythms: a new way to successfully manage depression J Psychopharmacol 24 2 Suppl. 2010 15 19
77. Y. Goto, S. Arai-Otsuki, Y. Tachibana, D. Ichikawa, S. Ozaki, and H. Takahashi Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity J Med Chem 49 2006 847 849
78. P. Govitrapong, S. Sawlom, and M. Ebadi The presence of delta and mu-, but not kappa or ORL(1) receptors in bovine pinealocytes Brain Res 951 1 2002 23 30
79. L.A. Graff, J.R. Walker, and C.N. Bernstein Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management Inflamm Bowel Dis 15 7 2009 1105 1118
80. M.K. Green, E.V. Barbieri, B.D. Brown, K.W. Chen, and D.P. Devine Roles of the bed nucleus of stria terminalis and of the amygdala in N/OFQ-mediated anxiety and HPA axis activation Neuropeptides 41 6 2007 399 410
81. M.K. Green, and D.P. Devine Nociceptin/orphanin FQ and NOP receptor gene regulation after acute or repeated social defeat stress Neuropeptides 43 6 2009 507 514
82. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, S.A. Leong, S.W. Lowe, and P.A. Berglund The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64 2003 1465 1475
83. G. Griebel, G. Perrault, and D.J. Sanger Orphanin FQ, a novel neuropeptide with anti-stress-like activity Brain Res 836 1-2 1999 221 224
84. H. Gu, D. Hu, X.R. Hong, J. Mao, Y. Cui, and N. Hui Changes and significance of orphanin and serotonin in patients with postpartum depression Zhonghua Fu Chan Ke Za Zhi 38 12 2003 727 728
85. R. Guerrini, G. Calo, A. Rizzi, R. Bigoni, C. Bianchi, and S. Salvadori A new selective antagonist of the nociceptin receptor Br J Pharmacol 123 1998 163 165
86. N. Hadrup, J.S. Petersen, S. Windfeld, L. Risom, C.B. Andersen, and S. Nielsen Differential down-regulation of aquaporin-2 in rat kidney zones by peripheral nociceptin/orphanin FQ receptor agonism and vasopressin typeâ€2 receptor antagonism J Pharmacol Exp Ther 323 2007 516 524
87. M.S. Harbuz, and S.L. Lightman Responses of hypothalamic and pituitary mRNA to physical and psychological stress in the rat J Endocrinol 122 3 1989 705 711
88. E. Haroon, C.L. Raison, and A.H. Miller Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior Neuropsychopharmacology 37 1 2012 137 162
89. E. Hashiba, K. Hirota, T. Kudo, G. Calo, R. Guerrini, and A. Matsuki Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs Naunyn Schmiedebergs Arch Pharmacol 367 2003 342 347
90. M.M. Heinricher Orphanin FQ/nociceptin: from neural circuitry to behavior Life Sci 73 2003 813 822
91. J.P. Herman, and W.E. Cullinan Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis Trends Neurosci 20 2 1997 78 84
92. J.M. Hettema, M.C. Neale, and K.S. Kendler A review and meta-analysis of the genetic epidemiology of anxiety disorders Am J Psychiatry 158 10 2001 1568 1578
93. I.B. Hickie, and N.L. Rogers Novel melatonin-based therapies: potential advances in the treatment of major depression Lancet 378 9791 2011 621 631
94. M.N. Hill, K.G. Hellemans, P. Verma, B.B. Gorzalka, and J. Weinberg Neurobiology of chronic mild stress: parallels to major depression Neurosci Biobehav Rev 36 9 2012 2085 2117
95. A. Hirao, A. Imai, Y. Sugie, T. Tamura, H. Shimokawa, and K. Toide Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl] -1H-benzimidazole, with anxiolytic potential Eur J Pharmacol 579 1-3 2008 189 195
96. A. Hirao, A. Imai, Y. Sugie, Y. Yamada, S. Hayashi, and K. Toide Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3- piperidinyl]-1H-benzimidazole as an anxiolytic agent J Pharmacol Sci 106 3 2008 361 368
97. P.V. Holmes Rodent models of depression: reexamining validity without anthropomorphic inference Trends Pharmacol Sci 15 2003 143 174
98. A. Holmes, M. Heilig, N.M. Rupniak, T. Steckler, and G. Griebel Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends Pharmacol Sci 24 11 2003 580 588
99. J. Huang, B. Young, M.T. Pletcher, M. Heilig, and C. Wahlestedt Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence Addict Biol 13 1 2008 88 94
100. F. Jenck, J.L. Moreau, J.R. Martin, G.J. Kilpatrick, R.K. Reinscheid, and F.J. Monsma Jr. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress Proc Natl Acad Sci 94 26 1997 14854 14858
101. F. Jenck, J. Wichmann, F.M. Dautzenberg, J.L. Moreau, A.M. Ouagazzal, and J.R. Martin A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc Natl Acad Sci 97 9 2000 4938 4943
102. C. Johansson, M. Jansson, L. Linnér, Q.P. Yuan, N.L. Pedersen, and D. Blackwood Genetics of affective disorders Eur Neuropsychopharmacol 11 2001 385 394
103. J. Kamei, Y. Matsunawa, S. Miyata, S. Tanaka, and A. Saitoh Effects of nociceptin on the exploratory behavior of mice in the hole-board test Eur J Pharmacol 489 1-2 2004 77 87
104. D.R. Kapusta Neurohumoral effects of orphanin FQ/nociceptin: relevance to cardiovascular and renal function Peptides 21 2000 1081 1099
105. D.R. Kapusta, J.K. Chang, and V.A. Kenigs Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats J Pharmacol Exp Ther 289 1999 173 180
106. E. Karamoysoyli, R.C. Burnand, D.R. Tomlinson, and N.J. Gardiner Neuritin mediates nerve growth factor-induced axonal regeneration and is deficient in experimental diabetic neuropathy Diabetes 57 2008 181 189
107. S. Kato, Y. Tsuzuki, R. Hokari, Y. Okada, J. Miyazaki, and K. Matsuzaki Role of nociceptin/orphanin FQ (Noc/oFQ) in murine experimental colitis J Neuroimmunol 161 2005 21 28
108. Y. Kawahara, M.B. Hesselink, G. van Scharrenburg, and B.H. Westerink Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala Eur J Pharmacol 485 1-3 2004 197 200
109. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, and K.R. Merikangas The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105
110. M. Koizumi, N. Midorikawa, H. Takeshima, and N.P. Murphy Exogenous, but not endogenous nociceptin modulates mesolimbic dopamine release in mice J Neurochem 89 2004 257 263
111. A. Köster, A. Montkowski, S. Schulz, E.M. Stübe, K. Knaudt, and F. Jenck Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice Proc Natl Acad Sci 96 18 1999 10444 10449
112. A.M. Kuopio, R.J. Marttila, H. Helenius, M. Toivonen, and U.K. Rinne The quality of life in Parkinson's disease Mov Disord 15 2 2000 216 223
113. D.G. Lambert The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nat Rev Drug Discov 7 8 2008 694 710
114. T.M. Largent-Milnes, and T.W. Vanderah Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat 20 2010 291 305
115. M. Lazzeri, G. Calò, M. Spinelli, R. Guerrini, S. Salvadori, and P. Beneforti Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study Urology 61 2003 946 950
116. M. Lazzeri, G. Calò, M. Spinelli, S. Malaguti, R. Guerrini, and S. Salvadori Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study J Urol 176 2006 2098 2102
117. M. Lazzeri, G. Calo', M. Spinelli, R. Guerrini, P. Beneforti, and S. Sandri Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study J Urol 166 2001 2237 2240
118. C. Le Cudennec, B. Naudin, J.C. Do Rego, and J. Costentin Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection Life Sci 72 2 2002 163 171
119. E. Le Maître, C. Vilpoux, J. Costentin, and I. Leroux-Nicollet Opioid receptor-like 1 (NOP) receptors in the rat dorsal raphe nucleus: evidence for localization on serotoninergic neurons and functional adaptation after 5,7-dihydroxytryptamine lesion J Neurosci Res 81 4 2005 488 496
120. A. Lecci, S. Giuliani, S. Meini, and C.A. Maggi Nociceptin and the micturition reflex Peptides 21 2000 1007 1021
121. A. Lecci, S. Giuliani, M. Tramontana, S. Meini, P. Santicioli, and C.A. Maggi Tachykinin-mediated effect of nociceptin in the rat urinary bladder in vivo Eur J Pharmacol 389 1 2000 99 102
122. M.G. Lee, B.J. Undem, C. Brown, and M.J. Carr Effect of nociceptin in acid-evoked cough and airway sensory nerve activation in guinea pigs Am J Respir Crit Care Med 173 2006 271 275
123. J.D. Leggett, K.L. Dawe, D.S. Jessop, and A.J. Fulford Endogenous nociceptin / orphanin FQ system involvement in hypothalamic-pituitary-adrenal axis responses: relevance to models of inflammation J Neuroendocrinol 21 11 2009 888 897
124. J.D. Leggett, M.S. Harbuz, D.S. Jessop, and A.J. Fulford The nociceptin receptor antagonist [Nphe1, Arg14, Lys15]nociceptin/orphanin FQ-NH2 blocks the stimulatory effects of nociceptin/orphanin FQ on the HPA axis in rats Neuroscience 141 4 2006 2051 2057
125. J.D. Leggett, D.S. Jessop, and A.J. Fulford The nociceptin/orphanin FQ antagonist UFP-101 differentially modulates the glucocorticoid response to restraint stress in rats during the peak and nadir phases of the hypothalamo-pituitary-adrenal axis circadian rhythm Neuroscience 147 3 2007 757 764
126. M.R. Lemke Depressive symptoms in Parkinson's disease Eur J Neurol 15 Suppl. 1 2008 21 25
127. B.E. Leonard The HPA and immune axes in stress: the involvement of the serotonergic system Eur Psychiatry Suppl. 3 2005 S302 S306
128. P.M. Luthra, S.K. Barodia, and R. Raghubir Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease J Neurosci Methods 178 2 2009 284 290
129. V. Madaan, and D.R. Wilson Neuropeptides: relevance in treatment of depression and anxiety disorders Drug News Perspect 22 6 2009 319 324
130. P. Madeddu, M.B. Salis, A.F. Milia, C. Emanueli, R. Guerrini, and D. Regoli Cardiovascular effects of nociceptin in unanesthetized mice Hypertension 33 1999 914 919
131. S. Mahmoud, W. Margas, C. Trapella, G. Calo, and V. Ruiz-Velasco Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons Mol Pharmacol 77 2010 804 817
132. B. Malinowska, G. Godlewski, and E. Schlicker Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system J Physiol Pharmacol 53 2002 301 324
133. M. Marti, R. Guerrini, L. Beani, C. Bianchi, and M. Morari Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat Neuroscience 112 1 2002 153 160
134. M. Marti, F. Mela, C. Veronesi, R. Guerrini, S. Salvadori, and M. Federici Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior J Neurosci 24 2004 6659 6666
135. M. Marti, S. Sarubbo, F. Latini, M. Cavallo, R. Eleopra, and S. Biguzzi Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease Mov Disord 25 11 2010 1723 1732
136. M. Marti, S. Stocchi, F. Paganini, F. Mela, C. De Risi, and G. Calo' Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex Br J Pharmacol 138 1 2003 91 98
137. M. Marti, C. Trapella, and M. Morari The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with l-DOPA J Neurochem 107 6 2008 1683 1696
138. M. Marti, C. Trapella, R. Viaro, and M. Morari The nociceptin/orphanin FQ receptor antagonist J-113397 and l-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway J Neurosci 27 6 2007 1297 1307
139. R.G. Maunder Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis, and future directions Inflamm Bowel Dis 11 6 2005 600 608
140. R.G. Maunder, and S. Levenstein The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence Curr Mol Med 8 4 2008 247 252
141. J. McDonald, G. Calo, R. Guerrini, and D.G. Lambert UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies Naunyn Schmiedebergs Arch Pharmacol 367 2003 183 187
142. B.S. McEwen Glucocorticoids, depression, and mood disorders: structural remodeling in the brain Metabolism 54 5 Suppl. 1 2005 20 23
143. R.L. McLeod, D.C. Bolser, Y. Jia, L.E. Parra, J.C. Mutter, and X. Wang Antitussive effect of nociceptin/orphanin FQ in experimental cough models Pulm Pharmacol Ther 15 2002 213 216
144. F. Mela, M. Marti, L. Ulazzi, E. Vaccari, S. Zucchini, and C. Trapella Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex Eur J Neurosci 19 5 2004 1317 1324
145. K.R. Merikangas, and N.C. Low Genetic epidemiology of anxiety disorders Handb Exp Pharmacol 169 2005 163 179
146. J.C. Meunier, C. Mollereau, L. Toll, C. Suaudeau, C. Moisand, and P. Alvinerie Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature 377 1995 532 535
147. K. Miyakawa, A. Uchida, T. Shiraki, K. Teshima, H. Takeshima, and S. Shibata ORL1 receptor-mediated down-regulation of mPER2 in the suprachiasmatic nucleus accelerates re-entrainment of the circadian clock following a shift in the environmental light/dark cycle Neuropharmacology 52 3 2007 1055 1064
148. C. Mollereau, and L. Mouledous Tissue distribution of the opioid receptor-like (ORL1) receptor Peptides 21 2000 907 917
149. D.A. Morilak, G. Barrera, D.J. Echevarria, A.S. Garcia, A. Hernandez, and S. Ma Role of brain norepinephrine in the behavioral response to stress Prog Neuropsychopharmacol Biol Psychiatry 29 8 2005 1214 1224
150. N.P. Murphy, H.A. Lam, Z. Chen, J.E. Pintar, and N.T. Maidment Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene Brain Res 953 1-2 2002 276 280
151. N.P. Murphy, H.T. Ly, and N.T. Maidment Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats Neuroscience 75 1 1996 1 4
152. N.P. Murphy, and N.T. Maidment Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis J Neurochem 73 1 1999 179 186
153. C. Mustazza, and G. Bastanzio Development of nociceptin receptor (NOP) agonists and antagonists Med Res Rev 31 2011 605 648
154. G.S. Naeve, M. Ramakrishnan, R. Kramer, D. Hevroni, Y. Citri, and L.E. Theill Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis Proc Natl Acad Sci 94 1997 2648 2653
155. P. Nativio, E. Pascale, A. Maffei, S. Scaccianoce, and F. Passarelli Effect of stress on hippocampal nociceptin expression in rat Stress 15 4 2012 378 384
156. C. Nazzaro, M. Barbieri, K. Varani, L. Beani, R.J. Valentino, and A. Siniscalchi Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor Neuropharmacology 58 2 2010 457 464
157. C. Nazzaro, S. Marino, M. Barbieri, and A. Siniscalchi Inhibition of serotonin outflow by nociceptin/orphaninFQ in dorsal raphe nucleus slices from normal and stressed rats: Role of corticotropin releasing factor Neurochem Int 54 5-6 2009 378 384
158. C.R. Neal Jr., A. Mansour, R. Reinscheid, H.P. Nothacker, O. Civelli, and H. Akil Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding J Comp Neurol 412 1999 563 605
159. C.R. Neal Jr., A. Mansour, R. Reinscheid, H.P. Nothacker, O. Civelli, and S.J. Watson Jr. Localization of orphanin FQ (nociceptin) peptide and messenger
160. E. Nedivi, G.Y. Wu, and H.T. Cline Promotion of dendritic growth by CPG15, an activityinduced signaling molecule Science 281 1998 1863 1866
161. C.B. Nemeroff, and M.J. Owens Treatment of mood disorders Nat Neurosci 5 2002 1068 1070 (Suppl.)
162. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 1 2002 13 25
163. M. Nibuya, S. Morinobu, and R.S. Duman Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments J Neurosci 15 11 1995 7539 7547
164. J.R. Nicholson, H. Akil, and S.J. Watson Orphanin FQ-induced hyperphagia is mediated by corticosterone and central glucocorticoid receptors Neuroscience 115 2 2002 637 643
165. M. Nishi, T. Houtani, Y. Noda, T. Mamiya, K. Sato, and T. Doi Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor EMBO J 16 8 1997 1858 1864
166. D.J. Nutt The neuropharmacology of serotonin and noradrenaline in depression Int Clin Psychopharmacol 17 2002 S1 S12
167. K. Okada, T. Sujaku, Y. Chuman, R. Nakashima, T. Nose, and T. Costa Highly potent nociceptin analog containing the Arg-Lys triple repeat Biochem Biophys Res Commun 278 2000 493 498
168. H. Okawa, M. Kudo, T. Kudo, R. Guerrini, D.G. Lambert, and T. Kushikata Effects of nociceptinNH2 and [Nphe1]nociceptin(1-13)NH2 on rat brain noradrenaline release in vivo and in vitro Neurosci Lett 303 3 2001 173 176
169. A.M. Ouagazzal, J.L. Moreau, M. Pauly-Evers, and F. Jenck Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene Behav Brain Res 144 2003 111 117
170. D.H. Overstreet, E. Friedman, A.A. Mathé, and G. Yadid The Flinders Sensitive Line rat: a selectively bred putative animal model of depression Neurosci Biobehav Rev 29 4-5 2005 739 759
171. S. Ozaki, H. Kawamoto, Y. Itoh, M. Miyaji, T. Azuma, and D. Ichikawa In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist Eur J Pharmacol 402 1-2 2000 45 53
172. J. Peluso, K.S. LaForge, H.W. Matthes, M.J. Kreek, B.L. Kieffer, and C. Gaveriaux-Ruff Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells J Neuroimmunol 81 1998 184 192
173. B. Petit-Demouliere, F. Chenu, and M. Bourin Forced swimming test in mice: a review of antidepressant activity Psychopharmacology (Berl) 177 3 2005 245 255
174. J.P. Redrobe, G. Calo', D. Regoli, and R. Quirion Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test Naunyn Schmiedebergs Arch Pharmacol 365 2002 164 167
175. R.K. Reinscheid, and O. Civelli The orphanin FQ/nociceptin knockout mouse: a behavioral model for stress responses Neuropeptides 36 2-3 2002 72 76
176. R.K. Reinscheid, H.P. Nothacker, A. Bourson, A. Ardati, R.A. Henningsen, and J.R. Bunzow Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor Science 270 1995 792 794
177. D. Reiss, A. Wolter-Sutter, W. Krezel, and A.M. Ouagazzal Effects of social crowding on emotionality and expression of hippocampal nociceptin/orphanin FQ system transcripts in mice Behav Brain Res 184 2 2007 167 173
178. J.M. Reul, I. Stec, M. Söder, and F. Holsboer Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system Endocrinology 133 1 1993 312 320
179. A. Rizzi, R. Bigoni, G. Marzola, R. Guerrini, S. Salvadori, and D. Regoli Characterization of the locomotor activityinhibiting effect of nociceptin/orphanin FQ in mice Naunyn Schmiedebergs Arch Pharmacol 363 2001 161 165
180. A. Rizzi, E.C. Gavioli, G. Marzola, B. Spagnolo, S. Zucchini, and R. Ciccocioppo Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl) piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies J Pharmacol Exp Ther 321 3 2007 968 974
181. A. Rizzi, S. Molinari, M. Marti, G. Marzola, and G. Calo' Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies Neuropharmacology 60 4 2011 572 579
182. A. Rizzi, C. Nazzaro, G.G. Marzola, S. Zucchini, C. Trapella, and R. Guerrini Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences Pain 124 1-2 2006 100 108
183. D. Rizzi, A. Rizzi, R. Bigoni, V. Camarda, G. Marzola, and R. Guerrini [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies J Pharmacol Exp Ther 300 2002 57 63
184. A. Rizzi, D. Rizzi, G. Marzola, D. Regoli, B.D. Larsen, and J.S. Petersen Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice Br J Pharmacol 137 3 2002 369 374
185. A. Rominger, S. Förster, J. Zentner, D.J. Dooley, A.T. McKnight, and T.J. Feuerstein Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices Br J Pharmacol 135 3 2002 800 806
186. B. Roozendaal, R. Lengvilas, J.L. McGaugh, O. Civelli, and R.K. Reinscheid Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation Learn Mem 14 1-2 2007 29 35
187. K. Rutten, J. De Vry, W. Bruckmann, and T.M. Tzschentke Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats Drug Alcohol Depend 114 2011 253 256
188. M.M. Ryan, H.E. Lockstone, S.J. Huffaker, M.T. Wayland, M.J. Webster, and S. Bahn Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes Mol Psychiatry 11 10 2006 965 978
189. K. Sakoori, and N.P. Murphy Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses Neuropsychopharmacology 33 4 2008 877 891
190. S. Sbrenna, M. Marti, M. Morari, G. Calo', R. Guerrini, and L. Beani Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin Br J Pharmacol 130 2 2000 425 433
191. E. Schlicker, and M. Morari Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system Peptides 21 2000 1023 1029
192. A. Serrano-Gomez, J.P. Thompson, and D.G. Lambert Nociceptin/orphanin FQ in inflammation and sepsis Br J Anaesth 106 2011 6 12
193. A. Serretti, and L. Mandelli The genetics of bipolar disorder: genome 'hot regions', genes, new potential candidates and future directions Mol Psychiatry 13 8 2008 742 771
194. J.R. Shoblock The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity CNS Drug Rev 13 2007 107 136
195. U. Simonsen, B.E. Laursen, and J.S. Petersen ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries Br J Pharmacol 153 6 2008 1185 1194
196. A. Siniscalchi, D. Rodi, L. Beani, and C. Bianchi Inhibitory effect of nociceptin on [3H]-5-HT release from rat cerebral cortex slices Br J Pharmacol 128 1 1999 119 123
197. A. Siniscalchi, D. Rodi, M. Morari, M. Marti, S. Cavallini, and S. Marino Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro Br J Pharmacol 136 8 2002 1178 1184
198. H. Son, M. Banasr, M. Choi, S.Y. Chae, P. Licznerski, and B. Lee Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress Proc Natl Acad Sci 109 28 2012 11378 11383
199. B. Spagnolo, G. Carra, M. Fantin, C. Fischetti, C. Hebbes, and J. McDonald Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1- yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies J Pharmacol Exp Ther 321 2007 961 967
200. T. Sugino, T. Shimazoe, M. Ikeda, and S. Watanabe Role of nociceptin and opioid receptor like 1 on entrainment function in the rat suprachiasmatic nucleus Neuroscience 137 2 2006 537 544
201. G.E. Tafet, and R. Bernardini Psychoneuroendocrinological links between chronic stress and depression Prog Neuropsychopharmacol Biol Psychiatry 27 6 2003 893 903
202. R. Tao, Z. Ma, M.M. Thakkar, R.W. McCarley, and S.B. Auerbach Nociceptin/orphanin FQ decreases serotonin efflux in the rat brain but in contrast to a kappa-opioid has no antagonistic effect on mu-opioid-induced increases in serotonin efflux Neuroscience 147 1 2007 106 116
203. S. Taylor, D.S. Thordarson, K.L. Jang, and G.J. Asmundson Genetic and environmental origins of health anxiety: a twin study World Psychiatry 5 2006 47 50
204. K. Teshima, M. Minoguchi, S. Tounai, A. Ashimori, J. Eguchi, and C.N. Allen Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W-212393 in rats Br J Pharmacol 146 1 2005 33 40
205. A.A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, and E. Vardy Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic Nature 485 2012 395 399
206. C. Trapella, R. Guerrini, L. Piccagli, G. Calo, G. Carra, and B. Spagnolo Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist Bioorg Med Chem 14 2006 692 704
207. H. Uchiyama, A. Toda, T. Hiranita, S. Watanabe, and R. Eyanagi Role of amygdaloid nuclei in the anxiolytic-like effect of nociceptin/orphanin FQ in rats Neurosci Lett 431 1 2008 66 70
208. H. Uchiyama, T. Yamaguchi, A. Toda, T. Hiranita, S. Watanabe, and R. Eyanagi Involvement of the GABA/benzodiazepine receptor in the axiolytic-like effect of nociceptin/orphanin FQ Eur J Pharmacol 590 1-3 2008 185 189
209. H. Ueda, T. Yamaguchi, S. Tokuyama, M. Inoue, M. Nishi, and H. Takeshima Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene Neurosci Lett 237 2-3 1997 136 138
210. K. Uezu, H. Sei, A. Sano, K. Toida, T. Suzuki-Yamamoto, and T. Houtani Lack of nociceptin receptor alters body temperature during resting period in mice Neuroreport 15 5 2004 751 755
211. G.B. Varty, L.A. Hyde, R.A. Hodgson, S.X. Lu, M.F. McCool, and T.M. Kazdoba Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species Psychopharmacology (Berl) 182 1 2005 132 143
212. G.B. Varty, S.X. Lu, C.A. Morgan, M.E. Cohen-Williams, R.A. Hodgson, and A. Smith-Torhan The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8- azabicyclo[3.2.1]octan-3-ol (SCH 221510) J Pharmacol Exp Ther 326 2 2008 672 682
213. C.W. Vaughan, and M.J. Christie Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones Br J Pharmacol 117 8 1996 1609 1611
214. R. Viaro, R. Sanchez-Pernaute, M. Marti, C. Trapella, O. Isacson, and M. Morari Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism Neurobiol Dis 30 2008 430 438
215. C. Vilpoux, L. Naudon, J. Costentin, and I. Leroux-Nicollet Chronic paroxetine increases [3H]nociceptin binding in rat dorsal raphe nucleus Neuroreport 13 1 2002 111 114
216. N.P. Visanji, R.M. de Bie, T.H. Johnston, A.C. McCreary, J.M. Brotchie, and S.H. Fox The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov Disord 23 2008 1922 1925
217. G. Vitale, R. Arletti, V. Ruggieri, C. Cifani, and M. Massi Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats Peptides 27 9 2006 2193 2200
218. G. Vitale, V. Ruggieri, M. Filaferro, C. Frigeri, S. Alboni, and F. Tascedda Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats Psychopharmacology (Berl) 207 2 2009 173 189
219. M. Volta, R. Viaro, C. Trapella, M. Marti, and M. Morari Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity Exp Neurol 228 2011 126 137
220. C. von Gall, J.H. Stehle, and D.R. Weaver Mammalian melatonin receptors: molecular biology and signal transduction Cell Tissue Res 309 2002 151 162
221. L.N. Wang, L.F. Liu, J.X. Zhang, and G.F. Zhao Plasma levels of nociceptin/orphanin FQ in patients with bipolar disorders and health adults Zhonghua Yi Xue Za Zhi 89 13 2009 916 918
222. F.M. Werner, and R. Coveñas Classical neurotransmitters and neuropeptides involved in major depression: a review Int J Neurosci 120 7 2010 455 470
223. K. Wibrand, E. Messaoudi, B. Håvik, V. Steenslid, R. Løvlie, and V.M. Steen Identification of genes co-upregulated with Arc during BDNFinduced long-term potentiation in adult rat dentate gyrus in vivo Eur J Neurosci 23 2006 1501 1511
224. P. Willner Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation Psychopharmacology (Berl) 134 1997 319 329
225. J. Witta, M. Palkovits, J. Rosenberger, and B.M. Cox Distribution of nociceptin/orphanin FQ in adult human brain Brain Res 997 2004 24 29
226. Y.L. Wu, L. Pu, K. Ling, J. Zhao, Z.J. Cheng, and L. Ma Molecular characterization and functional expression of opioid receptor-like1 receptor Cell Res 7 1 1997 69 77
227. G.X. Xie, E. Ito, K. Maruyama, Y. Suzuki, S. Sugano, and M. Sharma The promoter region of human prepro-nociceptin gene and its regulation by cyclic AMP and steroid hormones Gene 238 2 1999 427 436
228. X. Xuei, L. Flury-Wetherill, L. Almasy, L. Bierut, J. Tischfield, and M. Schuckit Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence Addict Biol 13 1 2008 80 87
229. T. Yamamoto, Y. Sakashita, and N. Nozaki-Taguchi Antagonism of ORLI receptor produces an algesic effect in the rat formalin test Neuroreport 12 7 2001 1323 1327
230. S. Yoshitake, S. Ijiri, J. Kehr, and T. Yoshitake Concurrent modulation of extracellular levels of noradrenaline and cAMP during stress and by anxiogenic- or anxiolytic-like neuropeptides in the prefrontal cortex of awake rats Neurochem Int 62 3 2013 314 323
231. E. Zambello, P.A. Jiménez-Vasquez, A. El Khoury, A.A. Mathé, and L. Caberlotto Acute stress differentially affects corticotropin-releasing hormone mRNA expression in the central amygdala of the "depressed" flinders sensitive line and the control flinders resistant line rats Prog Neuropsychopharmacol Biol Psychiatry 32 3 2008 651 661
232. P.F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, and P. Petrillo Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6- dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5- ol (SB-612111) J Pharmacol Exp Ther 308 2 2004 454 461
233. N.T. Zaveri The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications Curr Top Med Chem 11 9 2011 1151 1156
234. H.U. Zeilhofer, and G. Calo Nociceptin/orphanin FQ and its receptor - potential targets for pain therapy? J Pharmacol Exp Ther 306 2003 423 429
235. Z. Zhang, S.M. Xin, G.X. Wu, W.B. Zhang, L. Ma, and G. Pei Endogenous delta-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C J Neurochem 73 4 1999 1502 1509